Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. NOVO
  4. NOVO — Marts 2026

NOVO — Marts 2026

Planlagt Fastgjort Låst Flyttet NOVO
409 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #5

    NOVO-PARTNER: HALVDELEN AF VÆGTTABSKUNDER I USA STARTER ONLINE

    Hver anden person, der starter på vægttabsmedicin i USA, køber online. Det fortæller Zach Reitano, der er chef i telesundhedsselskabet Ro, i et interview med Børsen.

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #6

      FINANS.DK...

      ANALYTIKERE: NOVO ER NØDT TIL AT LAVE STORE OPKØB

      Novo Nordisk er nødt til at gennemføre store opkøb, hvis den danske medicinalkoncern skal kunne følge med den voksende konkurrence, lyder vurderingen fra analytikerne.

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #7

        Novos anbefaling sænkes til "neutral" hos Goldman Sachs https://proinvestor.com/investornyt/1416271/novos-anbefaling-saenkes-til-neutral-hos-goldman-sachs

        1 Reply Last reply
        0
        • Z Offline
          Z Offline
          Zuunes
          wrote on sidst redigeret af
          #8

          "Novo er nødt til at lave store opkøb" Hvorfor? Er så det store spørgsmål og hvad.. Alle de forslag jeg har hørt folk nævne i forhold til opkøb er jo syntetiske midler som jo slet ikke passer ind i hele novo nordisk maskine...

          1 Reply Last reply
          0
          • Z Offline
            Z Offline
            Zuunes
            wrote on sidst redigeret af
            #9

            Opkøb skal ihvertfald helt klart være med øje for teknologi.. Var jo primært Metseras HALO teknologi (1 måneds dosering) som man må gå ud fra var det strategiske mål i det bud.

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #10

              Godmorgen 🙂

              1 Reply Last reply
              0
              • L Offline
                L Offline
                LP90
                wrote on sidst redigeret af
                #11

                Godmorgen 🙂

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #12

                  Why I'm Not Worried About Novo Nordisk Stock https://www.fool.com/investing/2026/03/02/why-im-not-worried-about-novo-nordisk-stock/

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Stroka
                    wrote on sidst redigeret af
                    #13

                    God morgen 🙂

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #14

                      C25: Karakterbogen: Skuffende guidance for 2026
                      efterlader et svagt kursindtryk https://proinvestor.com/boards/131391

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #15

                        GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels https://www.fiercebiotech.com/research/glp-1s-support-heart-attack-recovery-rodents-relaxing-tight-blood-vessels

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          pauly
                          wrote on sidst redigeret af
                          #16

                          Den her lyder loven. Sematuglid i slidgigt https://www.sciencealert.com/semaglutide-may-reverse-damage-caused-by-osteoarthritis-study-suggests

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            pauly
                            wrote on sidst redigeret af
                            #17

                            lovende

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              pauly
                              wrote on sidst redigeret af
                              #18

                              Link Preview Image

                              favicon

                              X (formerly Twitter) (x.com)

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                pauly
                                wrote on sidst redigeret af
                                #19

                                Trænger vist til en ny staveplade, men i forstår nok budskabet

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  ProinvestorNEWS
                                  wrote on sidst redigeret af
                                  #20

                                  DNB Carnegie lowers its price target on $NVO to DKK 420 (from DKK 430) and reiterates its Buy rating.

                                  1 Reply Last reply
                                  0
                                  • C Offline
                                    C Offline
                                    Craw
                                    wrote on sidst redigeret af
                                    #21

                                    BLA resubmission and U.S. launch, following approval, expected in 2026. A meeting between FDA and Catalent Indiana occurred early in the first quarter of 2026. The meeting was constructive and included a discussion of Novo Nordisk’s progress remediating the Catalent Indiana facility. No additional corrective actions were requested by FDA. Scholar Rock plans to resubmit the apitegromab BLA following a successful reinspection of the site. Så fabrikken skulle gerne snart være oppe at køre

                                    1 Reply Last reply
                                    0
                                    • C Offline
                                      C Offline
                                      Craw
                                      wrote on sidst redigeret af
                                      #22

                                      https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-fourth-quarter-and-full-year-2025-financial?hl=pt-PT#:~:text=SMA Program,remediating the Catalent Indiana facility.

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #23

                                        Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports https://www.reuters.com/business/healthcare-pharmaceuticals/roche-targets-double-digit-market-share-weight-loss-aims-catch-up-with-novo-2026-03-03/

                                        1 Reply Last reply
                                        0
                                        • J Offline
                                          J Offline
                                          junklau
                                          wrote on sidst redigeret af
                                          #24

                                          Altså....Er det mig der bare ikke har hørt efter?Det lyder som en gamechancer, hvis Semaglutide kan opbygge væv i slidte knogleled? Ved nogen noget uddybende?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper